Intelligence · Clinical Development
Pipeline search results
Programs matching “multiple-myeloma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 167 pipeline programs matching "multiple-myeloma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Descartes-25
Cartesian Therapeutics
Multiple Myeloma
1 trial -
ENMD-2076
CASI Pharmaceuticals
Multiple Myeloma
1 trial -
FT576 (Allogenic CAR NK cells with BCMA expression)
Zafatek
Multiple Myeloma
1 trial -
Human BCMA targeted T Cells Injection
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
I-131-CLR1404
Cellectar Biosciences
Multiple Myeloma
1 trial -
IASO104
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Multiple Myeloma (RRMM)
1 trial -
IASO206 injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Multiple Myeloma (RRMM)
1 trial -
ICI201
The First People's Hospital of Lianyungang
Relapsed/Refractory Multiple Myeloma
1 trial -
ION251
IONIS PHARMACEUTICALS INC
Relapsed Multiple Myeloma
1 trial -
Ixazomib
Takeda
Relapsed and Refractory Multiple Myeloma
1 trial -
LCAR-B4822M CAR-T Cell Immunotherapy
Nanjing Legend Biotech Co.
Refractory or Relapsed Multiple Myeloma
1 trial -
LCAR-BCDR cells product
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
LCAR-BCX cells product
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
LGH447
Novartis Pharmaceuticals
Relapsed and Refractory Multiple Myeloma
1 trial -
LUCAR-B68 cells product
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
LVIVO-TaVec200 product
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
LVIVO-TaVec400 product
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma (MM)
1 trial -
Lenalidomide or Pomalidomide
ONCOLYTICS BIOTECH INC
Multiple Myeloma
1 trial -
Lintuzumab AC 225
Actinium Pharmaceuticals
Refractory Multiple Myeloma
1 trial -
NKTR-255
Nektar Therapeutics UK Limited
Multiple Myeloma
1 trial -
ORIC-533
Topiloric/Uriadec
Relapsed or Refractory Multiple Myeloma
1 trial -
PBCAR269A
Chongqing Precision Biotech Co., Ltd
Relapsed/Refractory Multiple Myeloma
1 trial -
PRT1419
Prelude Therapeutics Inc
Multiple Myeloma
1 trial -
QLS32015
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed/Refractory Multiple Myeloma (RRMM)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.